批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期 | 提交号 | 审批结论 | 申请内容分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
2022/04/29 |
SUPPL-5(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2022/02/04 |
SUPPL-1(补充) |
Approval |
Labeling |
STANDARD
|
|
|
2016/02/23 |
ORIG-1(原始申请) |
Approval |
|
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
无 |
与本品治疗等效的药品
活性成分:ETHINYL ESTRADIOL; NORGESTIMATE 剂型/给药途径:TABLET;ORAL-28 规格:0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG 治疗等效代码:AB
申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
076784 |
001 |
ANDA |
TRI LO SPRINTEC |
ETHINYL ESTRADIOL; NORGESTIMATE |
TABLET;ORAL-28 |
0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG |
Prescription |
No |
No |
AB |
2009/06/29
|
BARR LABS INC |
200541 |
001 |
ANDA |
NORGESTIMATE AND ETHINYL ESTRADIOL |
ETHINYL ESTRADIOL; NORGESTIMATE |
TABLET;ORAL-28 |
0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG |
Prescription |
No |
No |
AB |
2012/06/25
|
LUPIN PHARMS |
091232 |
001 |
ANDA |
TRI-LO-ESTARYLLA |
ETHINYL ESTRADIOL; NORGESTIMATE |
TABLET;ORAL-28 |
0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG |
Prescription |
No |
No |
AB |
2015/06/29
|
XIROMED |
204057 |
001 |
ANDA |
NORGESTIMATE AND ETHINYL ESTRADIOL |
ETHINYL ESTRADIOL; NORGESTIMATE |
TABLET;ORAL-28 |
0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG |
Prescription |
No |
Yes |
AB |
2016/02/23
|
GLENMARK SPECLT |
203873 |
001 |
ANDA |
NORGESTIMATE AND ETHINYL ESTRADIOL |
ETHINYL ESTRADIOL; NORGESTIMATE |
TABLET;ORAL-28 |
0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG |
Prescription |
No |
No |
AB |
2016/05/12
|
AMNEAL PHARMS |
205762 |
001 |
ANDA |
TRI-LO-MILI |
ETHINYL ESTRADIOL; NORGESTIMATE |
TABLET;ORAL-28 |
0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG |
Prescription |
No |
No |
AB |
2016/11/04
|
AUROBINDO PHARMA |
090541 |
001 |
ANDA |
TRI-LO-LINYAH |
ETHINYL ESTRADIOL; NORGESTIMATE |
TABLET;ORAL-28 |
0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG |
Prescription |
No |
No |
AB |
2022/09/02
|
NOVAST LABS |